{"id":371426,"date":"2026-01-31T13:00:13","date_gmt":"2026-01-31T13:00:13","guid":{"rendered":"https:\/\/www.europesays.com\/es\/371426\/"},"modified":"2026-01-31T13:00:13","modified_gmt":"2026-01-31T13:00:13","slug":"actualidad-para-la-innovacion-farmaceutica-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/es\/371426\/","title":{"rendered":"Actualidad para la innovaci\u00f3n farmac\u00e9utica"},"content":{"rendered":"<p>\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"225\" src=\"data:image\/svg+xml,%3Csvg%20xmlns=\" http:=\"\" class=\"isa-nb-item-img\" alt=\"\" data-lazy- data-lazy- data-lazy-src=\"https:\/\/www.europesays.com\/es\/wp-content\/uploads\/2026\/01\/fotonoticia_20260128171944_1920-1-300x225.jpg\"\/><\/p>\n<p><strong>Bayer<\/strong> ha recibido la autorizaci\u00f3n por parte de la Comisi\u00f3n Euopea (CE) por <strong>aflibercept<\/strong> 8m, 114,3 mg\/ml soluci\u00f3n inyectable (Eylea) para el tratamiento de pacientes con <strong>deterioro visual debido a edema macular<\/strong> tras una oclusi\u00f3n de la vena de la retina (OVR). Incluye la oclusi\u00f3n venosa de rama, central o hemirretiniana.<\/p>\n<p>En el ensayo Quasar, <strong>aflibercept<\/strong> 8mg mostr\u00f3 resultados funcionales y anat\u00f3micos no inferiores a los de aflibercept 2 mg, y el n\u00famero de pacientes que necesit\u00f3 unos intervalos de administraci\u00f3n mensuales (cada 4 semanas) fue tres veces menor, aun cuando todos los grupos pod\u00edan ampliar sus intervalos de dosificaci\u00f3n.<\/p>\n<p>Los pacientes tratados con <strong>aflibercept<\/strong> 8 mg despu\u00e9s de 3 inyecciones mensuales iniciales no solo mantuvieron la agudeza visual, sino que requirieron un promedio de <strong>2 a 3 inyecciones menos<\/strong> que los que recibieron aflibercept 2 mg (8,4 frente a 11,7) en la semana 64.<\/p>\n","protected":false},"excerpt":{"rendered":"Bayer ha recibido la autorizaci\u00f3n por parte de la Comisi\u00f3n Euopea (CE) por aflibercept 8m, 114,3 mg\/ml soluci\u00f3n&hellip;\n","protected":false},"author":2,"featured_media":342642,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[92],"tags":[25958,32585,25,24,9853,165,2217,7216,7288,166,23],"class_list":["post-371426","post","type-post","status-publish","format-standard","has-post-thumbnail","category-salud","tag-bayer","tag-d1","tag-es","tag-espana","tag-gsk","tag-health","tag-laboratorios","tag-lilly","tag-roche","tag-salud","tag-spain"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@es\/115989841473913523","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts\/371426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/comments?post=371426"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts\/371426\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/media\/342642"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/media?parent=371426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/categories?post=371426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/tags?post=371426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}